← Back to Search

Negative Emotions Impact on Decision-Making

N/A
Recruiting
Led By Silvia Lopez Guzman, M.D.
Research Sponsored by National Institute of Mental Health (NIMH)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up right after intervention
Awards & highlights
No Placebo-Only Group

Summary

This trial will study how negative emotions affect thinking and decision-making in healthy people to better understand mental disorders.

Who is the study for?
Healthy adults aged 18 to 55 who can understand and sign consent, read and write English. Excluded are those using psychoactive drugs or corticosteroids, pregnant women, NIMH staff/family, people with chronic pain or metal in the body that affects MRI scans, left-handed individuals for certain tests, and anyone with medical conditions affecting the study.
What is being tested?
The trial studies how negative emotions like stress, pain, and craving influence decision-making. Participants undergo emotional stressors (videos, math problems, heat/cold exposure), fill out questionnaires about their state of mind and personality traits while some also perform tasks during an fMRI brain scan.
What are the potential side effects?
There may not be direct side effects from the interventions as they involve non-invasive procedures such as watching videos or solving arithmetic problems. However discomfort from heat application or cold immersion could occur.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~right after intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and right after intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
BOLD signal in decision-making areas ROI
Value-based decision-making metrics
Secondary study objectives
Confidence
Interoceptive accuracy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Group I: 5Experimental Treatment1 Intervention
within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
Group II: 4Experimental Treatment1 Intervention
within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
Group III: 3Experimental Treatment1 Intervention
within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
Group IV: 2Experimental Treatment1 Intervention
within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
Group V: 1Experimental Treatment1 Intervention
within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)Lead Sponsor
2,936 Previous Clinical Trials
2,741,142 Total Patients Enrolled
Silvia Lopez Guzman, M.D.Principal InvestigatorNational Institute of Mental Health (NIMH)

Media Library

2 Clinical Trial Eligibility Overview. Trial Name: NCT05666726 — N/A
Frustration Research Study Groups: 2, 3, 1, 4, 5
Frustration Clinical Trial 2023: 2 Highlights & Side Effects. Trial Name: NCT05666726 — N/A
2 2023 Treatment Timeline for Medical Study. Trial Name: NCT05666726 — N/A
~527 spots leftby Dec 2026